AccurKardia Secures FDA 510(k) Clearance of and Launches AccurECG 2.0
Newly cleared AccurECG 2.0 is enterprise-grade, device-agnostic ECG interpretation platform designed for scale, accelerated turnaround, and flexible customer integrations.... Read more.
Coincheck Group Signs Agreement to Acquire 3iQ, a Global Pioneer in Digital Asset Investment Solutions
AMSTERDAM–(BUSINESS WIRE)–Coincheck Group N.V. (Nasdaq: CNCK, “Coincheck Group”), the holding company of Coincheck, Inc. (“Coincheck”), one of... Read more.
Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases
T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalities Cizutamig (BCMA TCE) positioned as first and best-in-class... Read more.
TransactionTree Appoints Kevin Saum as Chief Executive Officer to Lead Next Phase of Growth
ATLANTA–(BUSINESS WIRE)–TransactionTree, a retail technology company delivering a unified Customer360 Retail Operations Platform, today announced that... Read more.
Concord Appoints Chris Baker as Executive Chairman
Appointment underscores next phase of growth and innovation for leading data and analytics solutions provider MINNEAPOLIS–(BUSINESS WIRE)–#ConcordUSA–Concord,... Read more.
VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS
~ Designation enables an enhanced development path for VTx-002 and underscores its disease-modifying potential in ALS, a universally fatal disease with no cure ~... Read more.
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform
Financing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parabilis... Read more.
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030 WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca... Read more.
RPM Reports Fiscal 2026 Second-Quarter Results
Record second-quarter sales of $1.91 billion, an increase of 3.5% compared to the prior-year record Second-quarter net income of $161.2 million, diluted EPS of $1.26,... Read more.
Helen of Troy Limited Reports Third Quarter Fiscal 2026 Results
Consolidated Net Sales Decline of 3.4%GAAP Diluted Loss Per Share of $3.65Adjusted Diluted EPS of $1.71(1) Updates Fiscal 2026 Outlook:Consolidated Net Sales of... Read more.